Intraocular pressure modification

ABSTRACT

Assemblies and methods for modifying an intraocular pressure of a patient&#39;s one or both eyes are disclosed. The assemblies and methods can be used to treat, inhibit, or prevent ocular conditions such as glaucoma, high intraocular pressure, optic disc edema, idiopathic intracranial hypertension, zero-gravity induced papilledema, and other optic pressure related conditions. An assembly can include a goggle including at least one cavity, a pump in fluid communication with the at least one cavity, and a control mechanism. The control mechanism can be operatively coupled to the pump and can maintain a target pressure or target pressure range in the at least one cavity, which, when the assembly is worn by a patient, is the area between a patient&#39;s eye(s) and wall surfaces of the goggle. Controlling the pressure over the outer surfaces of the patient&#39;s eye(s) can drive a desired change in the intraocular pressure of the eye(s).

CLAIM OF PRIORITY

The present application is a Continuation application of U.S. patentapplication Ser. No. 13/790,048 filed May 8, 2013, which claims thebenefit of priority under 35 U.S.C. §119(e) to U.S. Provisional PatentApplication Ser. No. 61/609,078, filed on Mar. 9, 2012, and which areboth titled “INTRAOCULAR PRESSURE MODIFICATION,” and which are herebyboth incorporated by reference in their entirety.

TECHNICAL FIELD

This patent document pertains generally to ocular treatments. Moreparticularly, but not by way of limitation, this patent documentpertains to modifying an intraocular pressure of a patient's one or botheyes.

BACKGROUND

Glaucoma is a common chronic condition predominantly affecting membersof the elderly population. Glaucoma is a top cause of blindnessworldwide and it is the leading cause of irreversible blindnessworldwide. While glaucoma is not reversible, its progression can bestopped or slowed with treatment.

Most existing glaucoma treatments fall into one of two categories: eyedrop medications or invasive surgeries.

Eye drop medication (e.g., prostaglandins, beta blockers, carbonicanhydrate inhibitors, or alpha agonists) is typically the firsttreatment option since it can be effective for many patients and haverelatively low complication rates. Still, a significant number ofpatients (e.g., about 20% of patients) exist for whom eye dropmedication is ineffective. There is also a significant problem withpatient compliance in taking eye drop medication on a regular basis.Since glaucoma is a chronic condition and is not currently curable,glaucoma patients need to take their eye drop medication for the rest oftheir lives. It has been estimated that up to 50% of glaucoma patientsprescribed with an eye drop medication fail to successfully administertheir drops on a regular basis. This failure can be due to forgetting,difficulty getting the drops in one's eyes, reluctance to take long-termmedications, or unhappiness with certain side effects (e.g., redness ofthe eyes, eyelash growth, inflammation, orbital fat atrophy,discoloration of the iris or surrounding periorbital tissues,exacerbation of COPD or asthma, inhibition of corneal endothelial pumpfunction, exacerbation of corneal edema, or stinging upon instillation).

Various surgical options (e.g., laser trabeculoplasty, trabecularmeshwork stents, suprachoroidal stents, subconjunctival stents ortrabeculectomy or glaucoma tube shunts) are typically the secondtreatment option for glaucoma patients. Surgical options are moreinvasive and have can higher complication and morbidity rates ascompared to eye drop medication treatments.

OVERVIEW

While glaucoma is not reversible, its progression can be stopped orslowed with treatment directed to reducing intraocular pressure (“IOP”).The present inventors have recognized, among other things, that there isa need for a new non-invasive method of controlling IOP that does notrely on eye drop medication. This need is due to issues associated witheye drop medication compliance, the significant number of patients forwhom eye drop medication is ineffective, and complication and morbidityrates of surgery. The present invention provides assemblies and methodsfor modifying IOP in a patient's one or both eyes without the need forinvasive therapies or use of medications.

The assemblies and methods include variations of a goggle or gogglesconfigured to fit over one or both of a patient's eyes and means toalter a pressure inside one or more cavities of the goggle or goggles.An outer surface of the goggle or goggles can seal against a patient'sskin around a perimeter of his/her eye sockets. Subsequently, when themeans to alter pressure is actuated, a pressure differential fromatmospheric pressure can be created and maintained inside the one ormore goggle cavities and over one or both of the eyes. The cavitypressure can be either increased or decreased relative to atmosphericpressure, depending on a condition being treated (e.g., whether glaucomais being treated or whether papilledema is being treated). The change inpressure outside of the eye(s) can act to alter a pressure inside theeye(s) (e.g., IOP) through a resulting deflection of the shape of theeye(s), by driving a change in a rate of drainage of eye fluids througha trabecular meshwork, and/or from the pressure difference beingdirectly translated into the eye(s). The pressure can be altered by useof a small compressor or vacuum device (collectively a “pump”) in fluidcommunication with the one or more cavities of the goggle or goggles.

According to a first embodiment of an assembly, a goggle or goggles canbe configured to fit over one or both eyes of a patient and seal againstthe skin, around the eye sockets. The goggle or goggles can besufficiently air tight to allow a desired air pressure to be maintainedin one or more cavities inside the goggle or goggles and over theeye(s). The mechanism to alter the pressure inside the goggle cavitiescan be a portable reversible pump mounted to the goggle or goggles andin fluid communication with one or both sides of the goggle or goggles.The power supply for the pump can be a rechargeable or other batteryintegral to the goggle or goggles. The pump element can be actuated,manually or through programming, by the patient or a caregiver physicianto obtain a desired cavity pressure. To facilitate creation of thedesired cavity pressure, the pump can include a variable setting and/orthe assembly can include one or more vents.

According to a second embodiment of an assembly, a goggle or goggles canbe configured to fit over one or both eyes and seal against the skinaround the eye sockets. A small reversible pump having vacuum andpressure pump capabilities can be mounted remote to the goggle orgoggles and connected to one or more cavities inside the goggle orgoggles with one or more elongate tubes. The power supply for the pumpsystem can be a wall plug or a battery pack. The remote vacuum and/orpressure pump can be set by the patient or the caregiver physician for adesired pressure level, and can include a pressure measuring componentto allow automatic closed loop control of the pressure level.

According to a third embodiment of an assembly, a goggle or goggles canbe configured similar to the second embodiment, but further include apressure control mechanism in electronic communication with one or morebiosensors. The biosensors can be configured to monitor the IOP and/orthe cerebrospinal fluid (“CSF”) pressure (or surrogates for theseanatomic pressures). The biosensor monitoring can allow the gogglecavity pressure to be controlled to a target level determined by thereal time measured values for IOP and/or CSF pressure.

According to yet another embodiment of an assembly, the target pressureinside one or more cavities of a goggle or goggles can be altered in adesired sequence to optimize a desired change in the IOP. For example,it may be beneficial to cycle the pressure inside the goggle cavities toincrease the “pumping” action being driven through the trabecularmeshwork and into the anterior ciliary veins. By increasing the“pumping” action, a greater decrease in the IOP can be achieved in ashorter amount of time. Some users may find it desirable to minimize thetime that the goggle or goggles need to be worn. Optionally, theassembly, and specifically one or more cavities of the goggle orgoggles, can be configured to isolate the pressure effect over thetrabecular meshwork or the anterior ciliary veins of an eye to isolatethe pressure effects. A cavity of the goggle or goggles can, forexample, be segregated into distinct subcategories providing pressureeffects to certain portions of an eye (e.g., front portions of the eye)and not result in broader eye remodeling.

It is believed that the assemblies can be worn during the day, duringthe night, or for short durations throughout the day or night. Theappropriate duration and frequency of pressure modulation can varydepending on the condition being treated. By lowering IOP and equalizinga translaminar pressure gradient (e.g., if CSF pressure is low), axonaltransport can resume to meet metabolic needs of an optic nerve.Alternatively, raising IOP can equalize the translaminar pressuregradient (e.g., if the CSF pressure is high) and can allow axonaltransport to resume. This physiological improvement of axonal transportresumption can have lasting benefit for the optic nerve by allowing thetemporary resumption of normal metabolic functions, even if the IOPreverts to the atmospheric pressure after the goggle or goggles areremoved.

Normal IOP is in the range of 10-21 mmHG, while normal CSF pressure isin the range of 8-20 mmHG. The goggle or goggles can, in some examples,induce vacuum IOP up to 50 mmHG and can increase CSF pressure up to 50mmHG.

These and other examples and features of the present assemblies andmethods related to the assemblies will be set forth in part in followingDetailed Description. This Overview is intended to provide non-limitingexamples of the present subject matter—it is not intended to provide anexclusive or exhaustive explanation. The Detailed Description below isincluded to provide further information about the present assemblies andmethods.

BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, like numerals can be used to describe similar elementsthroughout the several views. Like numerals having different lettersuffixes can be used to represent different views of similar elements.The drawings illustrate generally, by way of example, but not by way oflimitation, various embodiments discussed in the present document.

FIG. 1 illustrates a side cross-sectional view of an eye.

FIG. 2 illustrates a side schematic view of an assembly, as constructedin accordance with at least one embodiment, positioned in front of aneye.

FIG. 3 illustrates an isometric view of an assembly, as constructed inaccordance with at least one embodiment.

FIG. 4 illustrates an isometric view of an assembly, as constructed inaccordance with at least one other embodiment.

DETAILED DESCRIPTION

FIG. 1 illustrates ocular structures in cross-section, which provide asuitable environment for using the present assemblies and methods. Afront surface of an eye is a cornea 101. Located behind the cornea 101is an anterior chamber or aqueous chamber 102. This is the primaryreservoir of aqueous humor inside the eye. Located behind the anteriorchamber 102 is a lens 103, and behind and around the lens 103 areciliary processes 105. The ciliary processes 105 are areas of the eyewhere aqueous humor is produced. The ciliary muscle 104 is roughly inthe same plane as the lens 103 and is positioned around the perimeter ofthe lens 103. A trabecular meshwork 106, Schlemm's canal, and anteriorciliary veins are all located below the anterior chamber 102 at thebottom of the cornea 101. This is the primary pathway for aqueous humorto exit the eye.

Behind the lens 103 and the ciliary processes 105 is the posteriorchamber of the eye filled with viscous humor 108. The viscous humor 108is distinct from the aqueous humor, but the separation between thechambers holding such fluids is elastic and, as such, the pressures ofthe two different humor fluids are equal or approximately equal. Anoptic nerve 107 connects to the back of the eye. A lamina cribrosa 111is the membrane over the junction of the optic nerve 107 and the eye.Cerebrospinal fluid 109 baths the optic nerve 107 behind the laminacribrosa 111 so that the lamina cribrosa is impacted on one side by thecerebrospinal fluid 109 pressure and on the other by the IOP.

During normal function of an eye, aqueous humor is produced inside theeye by the ciliary processes 105 in an anterior segment of the eye. Asaqueous humor is steadily produced, a like amount of fluid must exitfrom the anterior chamber 102 of the eye to maintain a balanced eyepressure. The aqueous humor can exit the anterior chamber 102 by one orboth of two main pathways. Some is reabsorbed by the uveoscleral outflowtract around the ciliary muscles 104. Some exits the eye though thetrabecular meshwork 106, a porous region in the front of the eye locatedbetween the cornea 101 and iris insertion. The aqueous fluid that exitsvia the trabecular meshwork flows through Schlemm's canal into theanterior ciliary veins. The present assemblies and methods can modifythe IOP in a patient's one or both eyes by altering the flow rate ofaqueous humor across the trabecular meshwork 106, Schlemm's canal, andthe anterior ciliary vein pathway.

FIG. 2 illustrates a side schematic view of an assembly, as constructedin accordance with at least one embodiment, positioned in front of aneye. The assembly can include a goggle or goggles 120, shown incross-section, including one or more cavities 122. The body of thegoggle or goggles 120 can be relatively rigid and made of an impermeableclear plastic so that it can maintain the differential pressure insidethe goggle or goggles, while allowing a patient wearing the goggle orgoggles to see outward. There can be a seal material 121 positionedaround a perimeter of the goggle body, which can create a seal betweenedges of the goggle or goggles and the patient's skin around the eyes.The seal material can be a softer rubber or plastic wiper held in closecontact with the skin by a strap around the head (not shown). The sealmaterial can alternatively be made of a compressible foam material, forexample.

The cavity area 122 inside the goggle or goggles 120 can have its airpressure altered by components of the assembly. The eye lid 110 is shownover the front of the eye. It can be seen in the schematic illustrationof FIG. 2 that the altered air pressure in the cavity area 122 can acton the entire area in front of the eye. This altered pressure can be areduced air pressure for patients with glaucoma or high IOP so that itacts to decrease the IOP. The altered pressure can be an increased airpressure for patients with optic disk edema (swelling of the laminacribrosa—see closing notes, below). The assembly can also be configuredto allow the altered pressure to be varied over time to different targetlevels if such configuration is found to be clinically desirable.

Bench testing utilizing the aforementioned techniques was conducted toinvestigate an effect on IOP of a vacuum applied to a convex surface ofa human cadaver eye. The experimental model involved mounting a fronthalf of an incised eye to an inside surface of a pressure vessel. A sealwas created between a perimeter of the incision and a surface of thepressure vessel so that the inside of the incised eye could bepressurized to a specified pressure or flow rate to simulate IOP. Thepressure vessel was then sealed, the initial IOP recorded, and vacuumsteps of 10 and 20 mmHg applied to the control volume above the convexsurface of the incised eye. The final IOP resulting from each vacuumstep was then recorded. Note that the lens of the incised eye had beenremoved and, while the trabecular meshwork was intact and functional,the urio scleral pathway and scleral muscles were not functional.

Two bench tests using this experimental model were conducted. In a firsttest, an initial IOP of 24.3 mmHg was reduced to 19.3 mmHg and 9.1 mmHgfor applied vacuums of 10 mmHg and 20 mmHg, respectively, returning to28.3 mmHg upon release of the vacuum. In a second test, an initial IOPof 28.3 mmHg was reduced to 19.4 mmHg and 10.4 mmHg for applied vacuumsof 10 mmHg and 20 mmHg, respectively, returning to 28.9 mmHg uponrelease of the vacuum. FIG. 3 illustrates an isometric view of anassembly in which a pressure control mechanism is mounted to a pair ofgoggles. The pressure control mechanism can include a pressure/vacuumpump 130. This pump 130 can be a compressor, a vacuum pump, orconfigured to be reversible so that the same goggles can be used foreither raising or lowering the pressure inside goggle cavities. Thepressure/vacuum pump 130 can be in fluid communication with the insideof the goggles through one or more pressure tubes 131. Power for thepressure/vacuum pump 130 can be supplied by a battery pack 132. Thepressure/vacuum pump can be actuated by means of an on/off switch 134. Aset point or rage for the target pressure can be set by means of anadjustable dial 133. The adjustable pressure set point or range cancontrol the pressure in a closed loop manner when a pressure sensormonitoring the pressure in the goggle cavities is used. Other means inwhich the adjustable pressure set point or range can be maintainedinclude controlling a speed of the pump 130 or controlling a vent in theassembly so that only a portion of the fixed speed pump is acting on thearea inside the goggle cavities.

FIG. 4 illustrates an isometric view of an assembly in which a pressurecontrol mechanism is mounted remote to the goggles. A pressure/vacuumpump 140 can be set on a side table and plugged into a wall socket forpower while the patient is sleeping or otherwise sedentary. Thepressure/vacuum pump 140 can also be clipped to a belt and powered witha battery pack if the patient desires to be mobile. In the illustratedexample, a pressure sensor 141 and a pressure control box 142 are shown.The pressure control box 142 can include the same or similar options ofcontrol as described in association with FIG. 3. The pressure sensor 141can be used if the control method used is closed loop based on amonitored pressure.

Optionally, the pressure control target set point or range can be variedby the pressure control box 142 in response to a signal sent fromanother sensor monitoring the patient's IOP and/or CSF pressure orsurrogates for one or both pressures. In this way, the pressure insidethe goggle cavities can be controlled to yield a targeted IOP based onreal time measurement of the IOP or CSF pressure.

To further describe the present assemblies and methods, a non-limitinglist of examples is provided here:

In Example 1, an assembly can comprise a goggle, a pump, and a controlmechanism. The goggle can include at least one cavity and can beconfigured to surround and be spaced from an eye. The pump can be influid communication with the at least one cavity. The control mechanismcan be operatively coupled to the pump, and can be configured to receivea target pressure setting and maintain the target pressure in the atleast one cavity through activation or deactivation of the pump.

In Example 2, the assembly of Example 1 can optionally be configuredsuch that the goggle can include a set of goggles including a firstcavity and a second cavity, the second cavity being spaced from thefirst cavity.

In Example 3, the assembly of Example 2 can optionally be configuredsuch that the pump is in fluid communication with the first cavity andthe second cavity.

In Example 4, the assembly of any one or any combination of Examples 1-3can optionally be configured such that the pump includes one or both ofa compressor device or a vacuum device.

In Example 5, the assembly of any one or any combination of Examples 1-4can optionally further comprise at least one transducer configured tomeasure a pressure in the at least one cavity and electronicallycommunicate the pressure to the control mechanism.

In Example 6, the assembly of Example 5 can optionally be configuredsuch that the at least one transducer is a pressure sensor configured tomonitor an intraocular pressure or a cerebrospinal fluid pressure.

In Example 7, the assembly of any one or any combination of Examples 1-6can optionally be configured such that the control mechanism comprises acontrol circuit configured to initiate a therapy cycle to the at leastone cavity based, in part, on the target pressure setting.

In Example 8, the assembly of any one or any combination of Examples 1-7can optionally further comprise a battery configured to provide power tooperate the pump and the control mechanism.

In Example 9, the assembly of any one or any combination of Examples 1-8can optionally be configured such that the goggle includes one or morevents fluidly coupling the at least one cavity and a surroundingenvironment.

In Example 10, the assembly of any one or any combination of Examples1-9 can optionally further comprise a seal member coupled to a perimeterof the goggle.

In Example 11, a method can comprise placing an assembly, including agoggle having at least one cavity, a pump in fluid communication withthe at least one cavity, and a control mechanism, over and around aneye, including spacing the goggle from a surface of the eye; setting atarget pressure within the at least one cavity using the controlmechanism; establishing the target pressure within the at least onecavity; and maintaining the target pressure within the at least onecavity for a period of time.

In Example 12, the method of Example 11 can optionally further compriseadjusting the target pressure.

In Example 13, the method of any one or any combination of Examples 11or 12 can optionally further comprise adjusting the target pressurebased, at least in part, upon measurement of at least one physiologicalparameter.

In Example 14, the method of any one or any combination of Examples11-13 can optionally be configured such that establishing the targetpressure include screating a pressure differential from atmosphericpressure in the at least one cavity.

In Example 15, the method of Example 14 can optionally be configuredsuch that creating the pressure differential from atmospheric pressurein the at least one cavity includes changing a shape of the eye orchanging a rate of drainage of an eye fluid through a trabecularmeshwork associated with the eye.

In Example 16, the method of any one or any combination of Examples11-15 can optionally be configured such that maintaining the targetpressure includes delivering a predetermined therapeutic pressure cycleto the eye.

In Example 17, the method of any one or any combination of Examples11-16 can optionally be configured such that maintaining the targetpressure includes maintaining a pressure in an operating range from −40mmHg to 40 mmHg (gage).

In Example 18, the method of Example 17 can optionally be configuredsuch that maintaining the pressure in the operating range includesmaintaining the pressure in an operating range from 5 mmHg to 20 mmHg(gage).

In Example 19, the method of any one or any combination of Examples11-18 can optionally be configured such that maintaining the targetpressure includes reducing an intraocular pressure of the eye.

In Example 20, the method of any one or any combination of Examples11-19 can optionally be configured such that maintaining the targetpressure includes inhibiting a progression of glaucoma associated withthe eye.

ELEMENT NUMERAL LIST

-   -   101—Cornea    -   102—Anterior chamber (aqueous chamber)    -   103—Lens    -   104—Ciliary muscle    -   105—Ciliary processes    -   106—Trabecular meshwork, Schlemm's canal, anterior ciliary veins        (all in close proximity)    -   107—Optic nerve    -   108—Viscous humors    -   109—Cerebrospinal fluid around optic nerve    -   110—Eye lid    -   111—Lamina cribrosa    -   120—Goggle body    -   121—Seal material around goggle perimeter    -   122—Cavity area inside goggle having an altered pressure    -   130—Pressure and/or vacuum pump (collectively referred to as a        “pump”)    -   131—One or more fluid lines connecting a pump to a goggle cavity        area    -   132—Rechargeable battery pack    -   133—Pressure adjusting control dial including a control circuit        (embodiment of “control mechanism”)    -   134—On/Off switch    -   140—Remote mounted pressure and/or vacuum pump    -   141—Pressure sensor    -   142—Pressure control box including a control circuit (embodiment        of “control mechanism”)

CLOSING NOTES

High IOP is a cause of glaucoma. Recent studies are showing that theremay be other causes of glaucoma in addition to IOP. IOP and other causesof glaucoma, including CSF pressure and optic disc edema, are believedto be treatable using the present assemblies and methods.

Cerebrospinal fluid bathes the spinal cord, brain, and optic nerve. Theoptic nerve is surrounded by CSF as it exits the intracranial vault andpasses through the orbit and is present all the way up to thetermination of the optic nerve as it enters the lamina cribrosaposterior in the eye. Glaucoma occurs at the optic nerve in the laminacribrosa. Since CSF bathes the optic nerve all the way to its entry inthe eye, it is reasonable to conclude that both pressurized fluids, IOPand CSF, exposed to the optic nerve can contribute to glaucoma and canbe treated using the present assemblies and methods.

Studies have shown that CSF pressure is low in patients with glaucoma.The CSF pressure is even lower in patients that have normal-tensionglaucoma and is higher and potentially protective in people that haveocular hypertension. These findings are consistent with the findingsseen in glaucomatous optic nerves where the optic nerve is bowed and thelamina cribrosa are bowed posterior. This is possibly caused by an IOPthat is higher than a CSF pressure creating a net force on the laminacribrosa that slowly remodels with time. It is also the opposite of whatis seen in idiopathic intracranial hypertension where elevated CSFpressure causes swelling and anterior bulging of the optic nerve.

If further testing shows that CSF is in fact a significant risk factorfor glaucoma in concert with IOP, then there can be a need for aglaucoma treatment similar to the present assemblies and methods thatcan be titrated to an appropriate level based on these two anatomicpressures for a patient.

Another condition effecting vision and related to these same anatomicpressures is optic disk edema or swelling. It is to be expected that theCSF pressure at the level of the eye can increase in a zero gravityenvironment as the eye is relatively high in the CSF cavity (spinalcord, brain, optic nerve). In a gravity environment, the CSF pressure ishigher in the caudal portion of the spinal cord due to gravity(analogous to pressure increasing as you go deeper under water). In zerogravity, this effect is not present, resulting in a relatively higherCSF pressure at the height of the optic nerve.

Optic disk edema also is seen in other patients possibly due to high CSFpressure relative to IOP. For these patients, there can be a need for atreatment such as the present assemblies and methods that enableincreasing the IOP to a targeted pressure relative to the CSF pressureto return the patients to a normal differential pressure across thelamina cribrosa.

The above Detailed Description includes references to the accompanyingdrawings, which form a part of the Detailed Description. The drawingsshow, by way of illustration, specific embodiments in which the presentassemblies and methods can be practiced. These embodiments are alsoreferred to herein as “examples.”

The above Detailed Description is intended to be illustrative, and notrestrictive. For example, the above-described examples (or one or moreelements thereof) can be used in combination with each other. Otherembodiments can be used, such as by one of ordinary skill in the artupon reviewing the above description (e.g., a goggle or gogglesincluding a single cavity or goggles having distinct cavities for eacheye). Also, various features or elements can be grouped together tostreamline the disclosure. This should not be interpreted as intendingthat an unclaimed disclosed feature is essential to any claim. Rather,inventive subject matter can lie in less than all features of aparticular disclosed embodiment. Thus, the following claims are herebyincorporated into the Detailed Description, with each claim standing onits own as a separate embodiment. The scope of the invention should bedetermined with reference to the appended claims, along with the fullscope of equivalents to which such claims are entitled.

In this document, the terms “a” or “an” are used to include one or morethan one, independent of any other instances or usages of “at least one”or “one or more.” In this document, the term “or” is used to refer to anonexclusive or, such that “A or B” includes “A but not B,” “B but notA,” and “A and B,” unless otherwise indicated. In this document, theterms “about” and “approximately” are used to refer to an amount that isnearly, almost, or in the vicinity of being equal to a stated amount.

In the appended claims, the terms “including” and “in which” are used asthe plain-English equivalents of the respective terms “comprising” and“wherein.” Also, in the following claims, the terms “including” and“comprising” are open-ended, that is, a system, kit, or method thatincludes elements in addition to those listed after such a term in aclaim are still deemed to fall within the scope of that claim. Moreover,in the following claims, the terms “first,” “second,” and “third,” etc.are used merely as labels, and are not intended to impose numericalrequirements on their objects.

The Abstract is provided to allow the reader to quickly ascertain thenature of the technical disclosure. It is submitted with theunderstanding that it will not be used to interpret or limit the scopeor meaning of the claims.

What is claimed is:
 1. An eye therapy assembly to treat an eye conditioncomprising: a compartment, defining at least one cavity, the compartmentsized and shaped to fit about at least a portion of an eye; a pump, influid communication with the at least one cavity; and a controlmechanism including a control circuit and an input, the controlmechanism coupled to the pump and configured to control the pump toapply, in the at least one cavity, an eye therapy target pressure levelthat is set by the control mechanism, using an indication of intraocularpressure (IOP) received at the input of the control mechanism, to treatthe eye condition in the eye.
 2. The eye therapy assembly of claim 1,comprising a pressure sensor in communication with the at least onecavity to measure the eye therapy target pressure level.
 3. The eyetherapy assembly of claim 1, comprising at least one biosensor operableto measure the indication of the intraocular pressure (IOP).
 4. The eyetherapy assembly of claim 3, wherein the at least one biosensorcomprises a plurality of biosensors including a biosensor to measure anindication of at least one of a CSF pressure or a translaminar pressuregradient.
 5. The eye therapy assembly of claim 4, wherein the pluralityof biosensors includes a CSF biosensor operable to measure an indicationof CSF pressure.
 6. The eye therapy assembly of claim 4, wherein theplurality of biosensors includes a translaminar pressure gradientbiosensor operable to measure at least an indication of the translaminarpressure gradient in the eye.
 7. The eye therapy assembly of claim 4,wherein the control mechanism includes a control circuit that isoperable to use at least one of the indication of translaminar pressuregradient, the indication of IOP, or the indication of CSF pressure toalter in a desired sequence the eye therapy target pressure level to theat least one cavity.
 8. The eye therapy assembly of claim 7, wherein thecontrol mechanism includes the control circuit that is operable to usethe indication of IOP measured by an IOP biosensor to alter in a desiredsequence the eye therapy target pressure level to the at least onecavity.
 9. The eye therapy assembly of claim 7, wherein the controlmechanism includes a control circuit that is operable to use theindication of CSF pressure measured by a CSF pressure biosensor to alterin a desired sequence the eye therapy target pressure level to the atleast one cavity.
 10. The eye assembly of claim 7, wherein the controlmechanism includes the control circuit that is operable to use theindication of translaminar pressure gradient measured by a translaminarpressure gradient biosensor to alter in a desired sequence the eyetherapy target pressure level to the at least one cavity.
 11. The eyetherapy assembly of claim 1, wherein the compartment includes one ormore vents fluidly coupling the at least one cavity with a surroundingenvironment, the one or more vents controlled to set or adjust the eyetherapy target pressure level inside the at least one cavity of thecompartment.
 12. The eye therapy assembly of claim 1, wherein at least aportion of the compartment defining the at least one cavity is clear soas to allow the eye of a patient to see outward.
 13. The eye therapyassembly of claim 1, wherein the at least one cavity is configured toisolate the eye therapy target pressure level over at least one of thetrabecular meshwork, the anterior ciliary veins, and the episcleralveins.
 14. The eye therapy assembly of claim 1, wherein the controlcircuit includes a second input configured to receive an indication ofthe eye therapy target pressure level to maintain the eye therapy targetpressure for a clinically desirable period of time that is therapeuticto treat the eye condition.
 15. The eye therapy assembly of claim 14,wherein maintaining the eye therapy target pressure level for aclinically desirable period of time that is therapeutic to threat theeye condition includes maintaining the eye therapy target pressure levelfor a frequency and duration sufficient to allow axonal transport toresume to treat the eye condition.
 16. The eye therapy assembly of claim1, wherein the control circuit includes a first output configured to setthe pump to generate the eye therapy target pressure level in anoperating range from −40 mmHg to 40 mmHg to treat the eye condition. 17.The eye therapy assembly of claim 16, wherein the control circuitincludes a first output configured to set the pump to generate the eyetherapy target pressure level in an operating range from −40 mmHg to 0mmHg to treat the eye condition, wherein the eye condition includesglaucoma.
 18. The eye therapy assembly of claim 16, wherein the controlcircuit includes a first output configured to set the pump to generatethe eye therapy target pressure level in an operating range from 0 mmHgto 40 mmHg to treat the eye condition, wherein the eye conditionincludes optic disc edema.
 19. An eye therapy assembly, the eye therapyassembly comprising: a compartment, defining at least one cavity, thecompartment sized and shaped to fit about at least a portion of an eye;a pump, in fluid communication with the at least one cavity; at leastone biosensor to monitor an indication of a translaminar pressuregradient; and a control mechanism including a control circuit, thecontrol mechanism coupled to the pump and the at least one biosensor,wherein the control circuit maintains a targeted translaminar pressuregradient selected to treat the eye by monitoring the indication of atranslaminar pressure gradient and applying an eye therapy targetpressure level to the at least one cavity to maintain the targettranslaminar pressure gradient.
 20. The eye therapy assembly of claim19, comprising a pressure sensor in communication with the at least onecavity to measure the eye therapy target pressure level.